Overview

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Status:
Not yet recruiting
Trial end date:
2023-06-16
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
Phase:
Phase 4
Details
Lead Sponsor:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Treatments:
Lurasidone Hydrochloride